Sanofi (SNYNF) Intangibles (2009 - 2025)
Sanofi (SNYNF) posted Intangibles of $30.6 billion for Q4 2025, up 32.18% sequentially from $23.1 billion in Q2 2025, and up 26.42% YoY from $24.2 billion in Q4 2024.
Sanofi (SNYNF) Intangibles (2009 - 2025) Analysis & Trends
Sanofi (SNYNF) has 17 years of Intangibles data on file, last reported at $30.6 billion in Q4 2025.
- Quarterly Intangibles rose 26.42% year-over-year to $30.6 billion in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $30.6 billion (up 26.42% YoY) and the FY2025 annual result came in at $30.6 billion, up 26.42% from the prior year.
- Intangibles rose to $30.6 billion in Q4 2025 per SNYNF's latest filing, from $23.1 billion in the prior quarter.
- The five-year high for Intangibles was $30.6 billion in Q4 2025, with the low at $22.1 billion in Q4 2022.
- Average Intangibles over 5 years is $25.3 billion, with a median of $24.3 billion recorded in 2021.
- The widest YoY moves for Intangibles: up 26.42% in 2025, down 19.42% in 2025.
- Sanofi's Intangibles stood at $24.5 billion in 2021, then fell by 9.84% to $22.1 billion in 2022, then increased by 18.51% to $26.2 billion in 2023, then fell by 7.58% to $24.2 billion in 2024, then climbed by 26.42% to $30.6 billion in 2025.
- Business Quant data shows SNYNF's Intangibles at $30.6 billion in Q4 2025, $23.1 billion in Q2 2025, and $24.2 billion in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 7.37 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 49.06 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 50.87 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 36.91 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 25.75 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 21.38 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 16.38 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 52.56 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | 11.30 Bn |
| 10 | Sanofi | - | - | 9.49 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 30.57 Bn |
| Jun 30, 2025 | 23.13 Bn |
| Dec 31, 2024 | 24.18 Bn |
| Jun 30, 2024 | 28.70 Bn |
| Dec 31, 2023 | 26.17 Bn |
| Jun 30, 2023 | 26.78 Bn |
| Dec 31, 2022 | 22.08 Bn |
| Jun 30, 2022 | 23.45 Bn |
| Dec 31, 2021 | 24.49 Bn |
| Jun 30, 2021 | 23.44 Bn |
| Dec 31, 2020 | 21.87 Bn |
| Jun 30, 2020 | 18.75 Bn |
| Dec 31, 2019 | 4.21 Mn |
| Jun 30, 2019 | 21.46 Bn |
| Dec 31, 2018 | 24.98 Bn |
| Sep 30, 2018 | 87.23 Mn |
| Jun 30, 2018 | 106.22 Mn |
| Mar 31, 2018 | 25.81 Bn |
| Dec 31, 2017 | 15.40 Bn |
| Jun 30, 2017 | 15.23 Bn |